Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Tildrakizumab for Psoriasis
Recruiting3 awardsPhase 4
Boston, Massachusetts
This trial will test whether the FDA approved drug Tildrakizumab, which blocks the Th17 pathway of inflammation, can improve coronary vascular function and coronary flow reserve in people with psoriasis.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.